Genetic Technologies (ASX:GTG) Remains Suspended as Company Works Through Reinstatement Process

Aditi Sarkar

25 August 2026 11:48 AM AEST

Genetic Technologies (ASX:GTG) Remains Suspended as Company Works Through Reinstatement Process

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Genetic Technologies (ASX:GTG) remains suspended from Quotation following a voluntary administration process.
The suspension relates to administration and compliance requirements rather than confirmed unpaid listing fees.
The company completed a Recapitalisation process and exited external administration in 2025.
Investors are monitoring financial reporting, reinstatement conditions and future Business direction.

Genetic Technologies (ASX:GTG), a molecular diagnostics company with a long history across Australian and international markets, remains suspended from quotation on the Australian Securities Exchange as at 24 August 2026.

The company’s suspension has been linked to a period of financial distress, external administration and subsequent restructuring rather than a listing fee issue. Claims suggesting a fresh suspension due to unpaid annual listing fees could not be independently verified.

The company has since undergone significant changes, including the sale of key operating businesses and a recapitalisation process, leaving investors focused on whether it can satisfy ASX requirements and return to quotation.

Key Development

Genetic Technologies entered voluntary suspension on 21 October 2024 while it worked through strategic and funding matters.

The situation escalated in November 2024 when voluntary administrators from FTI Consulting were appointed to the company. Following the appointment, GTG securities remained suspended under ASX Listing Rule 17.3.

Creditors later approved a Deed of Company Arrangement (DOCA) proposed by Benelong Capital Partners, allowing the company to exit external administration and restructure its balance sheet.

The DOCA became effective in May 2025, resulting in a recapitalised company structure and a reconstituted board.

However, exiting administration did not automatically restore trading. GTG securities remained suspended as the company continued to address ASX compliance and reinstatement requirements.

Available records indicate that the continued suspension relates to reporting obligations and reinstatement conditions rather than a confirmed listing fee default.

Financial Position

Genetic Technologies’ current financial position remains difficult to assess due to limited availability of complete, independently verified financial information.

During the restructuring process, the company sold key operating assets, including its geneType risk-assessment business and direct-to-consumer DNA brands.

Following these transactions, the company’s focus shifted away from its previous diagnostics operations towards identifying future strategic opportunities.

The company continued lodging some financial updates during the restructuring period, but outstanding reporting obligations have remained an important Factor in its suspended status.

With trading unavailable since 2024, historical share prices do not provide a reliable indication of current value. The recapitalisation process also significantly changed the company’s capital structure.

Management View

Following the administration process, management shifted its focus towards rebuilding the company and exploring new strategic opportunities.

In 2025, Genetic Technologies announced proposed acquisitions of financial-services businesses as part of a potential new direction.

However, in March 2026 the company announced that it would no longer proceed with those acquisitions following a strategic review.

The company has since focused on evaluating alternative opportunities while working towards compliance requirements.

GTG also announced the termination of its American Depositary Receipt facility, reflecting further changes to its international market structure.

Investor Focus

For shareholders, the primary issue remains the continued suspension of GTG securities.

Without active trading, investors cannot buy or sell shares through the ASX market, leaving the company’s valuation difficult to assess.

The company’s future depends on whether it can satisfy ASX reinstatement requirements and establish a credible forward business strategy.

The possibility of using the listed structure for a future transaction remains a potential pathway, but this depends on identifying suitable opportunities and meeting regulatory requirements.

Future Catalysts

The most important catalyst for Genetic Technologies would be a successful return to ASX quotation.

This would require the company to complete outstanding reporting obligations, satisfy ASX listing requirements and demonstrate a viable future business direction.

A new acquisition, strategic transaction or recapitalisation initiative could also influence the company’s outlook.

Progress on any future corporate transaction would likely be a key milestone for shareholders monitoring the suspended entity.

Key Risks

The primary risk is that Genetic Technologies fails to meet ASX reinstatement requirements within the required timeframe.

A prolonged suspension could increase the risk of removal from the official list, leaving shareholders with an Illiquid security.

The company also faces execution risk around identifying and completing a future strategic transaction.

Any new Acquisition or capital raising may result in further dilution for existing shareholders.

The lack of complete current financial information remains another important uncertainty for investors assessing the company’s position.

Investor Takeaway

Genetic Technologies (ASX:GTG) remains suspended after undergoing voluntary administration, recapitalisation and a major restructuring process.

The available record does not support claims that the suspension was caused by unpaid listing fees. Instead, the company’s current status is linked to its administration history, reporting obligations and ASX reinstatement requirements.

The key factors for investors to monitor are the completion of compliance requirements, identification of a future business direction and any announcement regarding a return to quotation.

Until those steps occur, GTG remains a suspended company where future value depends on successful restructuring and execution.

FAQs

Q: Why is Genetic Technologies (ASX:GTG) suspended?

A: GTG remains suspended following administration, restructuring and ongoing compliance requirements.

Q: Is GTG suspended due to unpaid listing fees?

A: This has not been independently verified; available records indicate administration and compliance issues.

Q: What happened to Genetic Technologies’ previous businesses?

A: The company sold key diagnostics-related businesses during its restructuring process.

Q: What are investors watching for GTG?

A: Investors are monitoring reinstatement progress, reporting obligations and future business plans.

Q: Can shareholders currently trade GTG shares?

A: No, the company’s securities remain suspended from quotation.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.